Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Jednoramenná multicentrická studie hodnotící přijetí a proveditelnost digitálního nástroje pro vzdálené monitorování přizpůsobeného pacientům s ATTR-CM: ACO-Monitor (ACO-MONITOR)

23. října 2026 aktualizováno: Bayer

Observační studie ke zjištění přijatelnosti a praktičnosti digitálního nástroje pro vzdálené monitorování (Luscii) u lidí s transtyretinovou amyloidní kardiomyopatií (ATTR-CM)

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid in the heart muscle. This build-up makes the heart stiff and can lead to symptoms of heart failure, such as difficulty breathing, tiredness, swelling in the legs, and reduced ability to be physically active. ATTR-CM occurs in two forms: a hereditary (variant) type caused by changes in genes, and a wild-type form that usually develops with aging.

People living with ATTR-CM are usually cared for at specialist centers, which may require them to travel long distances for appointments. Because of this, visits may be infrequent, and sometimes people only see their doctor once a year. This can make it harder to notice if the disease is getting worse or if there are problems with following their treatment plan. As a result, important changes in health may go unnoticed for several months, which can be risky.

Remote monitoring offers a way for people living with ATTR-CM and their healthcare professionals to stay connected between clinic visits. Recent studies have shown that remote monitoring can help by making it easier to share health information, spot problems earlier, and support people to follow their treatment plans. This can lead to fewer hospital visits and better health outcomes.

Luscii is a digital remote monitoring tool designed to help people living with ATTR-CM and their healthcare professionals stay connected between clinic visits. Luscii has two main parts: Luscii contact, a smartphone app that allows secure messaging and video calls, and Luscii vitals, a clinical software system that organizes health data and can alert the healthcare team if there are changes that need attention. Luscii vitals is a CE-marked medical device used within its approved purpose and does not replace a doctor's judgement.

By making it easier to communicate and share information, Luscii aims to support earlier detection of problems, better management of ATTR-CM, and a more positive experience for people living with this condition.

The main purpose of this observational study, called ACO-MONITOR, is to learn how acceptable and practical Luscii is for people living with ATTR-CM and their healthcare professionals. The study will take place in Austria, Germany, and Italy at three specialist centers. About 60 adults with a diagnosis of hereditary or wild-type ATTR-CM will be invited to take part. There will be no treatments given as part of this study. Instead, participants will use the Luscii app and devices at home to track their health and share information with their healthcare professionals. The study team will provide training on how to use Luscii and will help participants get started.

The study team will look at:

  • How quickly and how often participants and healthcare professionals use Luscii
  • How long Luscii is used by each person
  • How many times participants use Luscii after being reminded
  • How easy Luscii is to use, based on questionnaires for both participants and healthcare professionals

The study will last about 18 months in total, including a 6-month period to invite participants and a 12-month follow-up period. During the study, the study team will:

  • Support participants in using Luscii to share health information from home
  • Monitor how often and how easily Luscii is used
  • Ask participants and healthcare professionals about their experiences using Luscii, including what worked well and what could be improved
  • Record any problems or technical issues with using Luscii By collecting this information, the researchers hope to learn if Luscii can help improve communication, support earlier detection of health problems, and make it easier for people living with ATTR-CM to manage their condition between clinic visits.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Typ studie

Pozorovací

Zápis (Odhadovaný)

60

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

      • Pavia, Itálie, 27100
        • Policlinico San Matteo di Pavia
      • Heidelberg, Německo, 69120
        • Universitätsklinikum Heidelberg
      • Innsbruck, Rakousko, 6020
        • Medizinische Universität Innsbruck

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Ukázka pravděpodobnosti

Studijní populace

Eligible participants will be invited by their treating physician and, after providing informed consent, will be observed for approx. 12 months. Patients with an established diagnosis of either wild-type or variant ATTR-CM can be enrolled. Evidence of assessment of all eligibility criteria by the physician or a delegate, as well as enrolment of a participant in the study should be documented in the participant medical records. Medical professionals who are directly involved in the participants' treatment and who have access to and will review the Luscii-captured data for routine care are asked to complete the study-specific questionnaires/forms.

Popis

Inclusion Criteria:

For patients:

  • Adult (≥18 years at the date of signing the informed consent form (ICF)).
  • Diagnosis of either wild-type or variant ATTR-CM.
  • Treatment with a drug approved for ATTR-CM, including newly prescribed therapy at the initial visit.
  • Signed ICF.
  • Access to and basic ability to use a personal smartphone with internet connectivity sufficient to install and operate the Luscii contact application.

For medical professionals:

  • Directly involved in the treatment or clinical management of the enrolled ATTR-CM participants and having access to and reviewing the Luscii-captured data for routine care.
  • Agreement to ICF within the EDC system for the purpose of using Luscii or to complete the HCP Experience Questionnaire.

Exclusion Criteria:

For patients:

  • Participation in an investigational program with interventions outside of routine clinical practice.
  • Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.

For medical professionals:

  • Any current affiliation with Luscii, Bayer, or any of their affiliates.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Wild-type or variant ATTR-CM participants

Participants will be enrolled after the decision to initiate the use of the digital remote monitoring tool, Luscii, as per standard use.

The Luscii tool (CE class IIa certification) will be utilized for remote monitoring of health data specific to ATTR-CM patients. Following the observational nature of the study, no additional interventions will be implemented beyond the standard use of the Luscii tool. Participants will use the Luscii tool continuously throughout the observational period, which is approximately 12 months.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Acceptance of Luscii among medical professionals
Časové okno: At baseline (initial visit), at 6 months and at 12 months

Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii vitals and Luscii contact throughout the study period.

At baseline (initial visit), at 6 months and at 12 months
Acceptance of Luscii among participants with ATTR-CM
Časové okno: At baseline (initial visit), at 6 months and at 12 months

Defined as their willingness to adopt and engage with the ATTR-CM-specific configuration of Luscii contact throughout the observational period.

At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for medical professionals
Časové okno: At baseline (initial visit), at 6 months and at 12 months

Defined as the practicality of implementing the tool in real-world ATTR-CM care throughout the study period.

At baseline (initial visit), at 6 months and at 12 months
Feasibility of Luscii for participants with ATTR-CM
Časové okno: At baseline (initial visit), at 6 months and at 12 months

Defined as the practicality of using the tool in real-world settings throughout the observational period.

At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among participants
Časové okno: At baseline (initial visit), at 6 months and at 12 months

Measured by the Patient Experience Questionnaire

At baseline (initial visit), at 6 months and at 12 months
Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among medical professionals
Časové okno: At baseline (initial visit), at 6 months and at 12 months

Measured by the Healthcare Professional (HCP) Experience Questionnaire

At baseline (initial visit), at 6 months and at 12 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Počet pacientů, kteří neprošli screeningem
Časové okno: Při výchozím stavu (úvodní návštěva)
Při výchozím stavu (úvodní návštěva)
Důvod selhání screeningu
Časové okno: Na začátku (úvodní návštěva)
Na začátku (úvodní návštěva)
Participant demographic characteristics: age
Časové okno: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline (initial visit)

At baseline (initial visit)
Participant demographic characteristics: sex
Časové okno: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline

At baseline (initial visit)
Participant demographic characteristics: race
Časové okno: At baseline (initial visit)

Demographic characteristics of participants with ATTR-CM who are willing to use a digital remote tool at baseline

At baseline (initial visit)
Clinical characteristics: National Amyloidosis Centre (NAC) Stage
Časové okno: At baseline (initial visit)

Categorization of participants according to the NAC Stage into stages I, II, or III, with stage III indicating a higher risk of mortality

At baseline (initial visit)
Clinical characteristics: relevant comorbidities
Časové okno: At baseline (initial visit)

ATTR-CM relevant comorbidities

At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM prior medications
Časové okno: At baseline (initial visit)

Concomitant medications administered within the past 12 months before initial visit

At baseline (initial visit)
Treatment patterns with Acoramidis: ATTR-CM concomitant medications
Časové okno: At baseline (initial visit)

Previously administered ATTR-CM related medications within the past 12 months before initial visit

At baseline (initial visit)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

30. října 2026

Primární dokončení (Odhadovaný)

15. dubna 2028

Dokončení studie (Odhadovaný)

15. května 2028

Termíny zápisu do studia

První předloženo

23. dubna 2026

První předloženo, které splnilo kritéria kontroly kvality

23. dubna 2026

První zveřejněno (Aktuální)

29. dubna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

26. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

23. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 23127

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .